Roivant Sciences LTD 10-Q quarterly reports

Roivant Sciences Ltd. filed its quarterly report for the period ended June 30, 2026, detailing a net loss of $290.6 million and increased operating expenses, while maintaining a substantial cash reserve of $3.8 billion.

Roivant Sciences reported a significant net loss for Q3 2025, driven by increased R&D and G&A expenses, despite a strong cash position and ongoing clinical pipeline progress.

Roivant Sciences Ltd. reported an increased net loss for the six months ended September 30, 2025, driven by higher R&D expenses and lower revenue, despite significant clinical trial advancements and a strong cash position.

Roivant Sciences reported a significant net loss from continuing operations in Q1 2025, driven by increased R&D and G&A expenses, while maintaining a strong cash position and advancing its diverse pipeline.

Roivant Sciences reports a net loss of $104.36 million for the nine months ended December 31, 2024, while strategically advancing its pipeline and completing the sale of Dermavant.

Roivant Sciences reported its second quarter 2024 results, showcasing a net loss but also highlighting strategic progress, pipeline advancements, and a strong cash position.

Dermavant Sciences Ltd. has amended its existing credit agreement and revenue interest purchase agreement, while also securing an equity commitment from its parent company.

Roivant Sciences Ltd. announces its financial results for the quarter ended December 31, 2023, including a significant gain from the sale of Telavant and updates on its pipeline.